HUMIRA® for HCPs
SkyRizi™ for HCPs
RINVOQ™ for HCPs

NOW APPROVED For moderate to severe rheumatoid arthritis (RA) in adult MTX-IR patients1

Older woman in a harnass, ziplining Older woman in a harnass, ziplining Older woman in a harnass, ziplining
Abbvie's commitment to exceptional access and product experience Abbvie's commitment to exceptional access and product experience Abbvie's commitment to exceptional access and product experience

Get started with the
Enrollment & Prescription Form

Commitment to working toward 100% commercial patient access Commitment to working toward 100% commercial patient access Commitment to working toward 100% commercial patient access

Building toward HUMIRA-Level Coverage

Red thermometer

97%

Preferred2*

2019 national commercial, Medicare Part D, and Medicaid as of January, 20192

 
Yellow thermometer

20%

Coverage3*

2019 national commercial coverage updated as of October, 20193

 

*Formulary definitions: Coverage means placed on formulary without a single step edit through other biologics. For RINVOQ, this could include coverage on a non‑preferred tier which may result in a higher out‑of‑pocket cost. Preferred/Step 1 means the product is placed on the plan's preferred formulary. Non‑preferred products require a higher out‑of‑pocket cost or step edit, or are placed on a higher tier.

Commercial patients not yet covered are eligible to RINVOQ from RINVOQ Complete Commercial patients not yet covered are eligible to RINVOQ from RINVOQ Complete Commercial patients not yet covered are eligible to RINVOQ from RINVOQ Complete
0

If your eligible RINVOQ patient’s commercial insurance experiences an initial delay or denial, they may still be able to access their prescribed therapy at no charge while coverage is established, up to 24 months.*

Day and time

Complete and send the single Enrollment and Prescription form to RINVOQ Complete. Your Access Specialist will call your office with next steps.

Get started with the enrollment & prescription form

*Program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patient will no longer be eligible to participate in program. Available to patients between the ages of 18-63 with commercial prescription insurance coverage who meet eligibility criteria. Eligibility: Patients must be diagnosed with moderate to severe rheumatoid arthritis, have a valid prescription for RINVOQ™ and participate in a commercial insurance plan that has denied or not yet made a formulary decision for RINVOQ. Once the patient’s insurance plan has made a formulary decision and established a process for reviewing coverage requests for RINVOQ, continued eligibility for the program requires the submission of a Prior Authorization prior to the next scheduled dose and appeal of the coverage denial within 180 days. Program provides RINVOQ at no charge to patients for up to 2 years or until they receive insurance coverage approval, whichever occurs earlier. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage.

Available only to patients with commercial insurance who meet eligibility criteria. See enrollment form for full Terms and Conditions.

brushstroke

One EXCEPTIONAL patient experience

Handshake

NURSE
AMBASSADORS*

Empower patients

Our Nurse Ambassadors are the heart of RINVOQ Complete

Nurse Ambassadors provide 1:1 support to help meet the unique needs of each individual patient, including:

  • Committed to answering questions throughout the experience to help avoid disruptions.
  • Answer patients’ insurance questions, help them identify ways to save on prescription costs, and connect them with additional insurance expertise.

To have your patients connect with a
Nurse Ambassador, call
1‑800-2-RINVOQ (1‑800‑274‑6867)

Talk to us

NEW ACCESS
SPECIALISTS

Insurance support when needed

  • Resource with expertise on Medicare and commercial plans at a national, local, and program level so that they can educate on potential options to consider based on each patient’s unique financial situation.
  • Can educate on payer prior authorization and appeal processes so you can determine the best access solution for each patient’s unique situation.

For support in person or over the phone, call
1‑877‑COMPLETE (1‑877‑266‑7538)

credit cards

ACCESS & SUPPORT

Help with access &
treatment affordability

RINVOQ Complete can help your commercial patients save: 

  • With the RINVOQ Complete Savings Card, your eligible commercially insured patients may pay as little as $5 per monthly dose.
  • RINVOQ Complete may help eligible commercially insured patients experiencing initial coverage delays or denials access their prescribed therapy at no charge while coverage is established.


For more information about Eligibility Criteria, call
1-800-2-RINVOQ (1-800-274-6867)

*Ambassadors do not provide medical advice and are trained to direct patients to speak with their healthcare professional about any treatment-related questions, including further referrals.

†Terms and Conditions apply. This benefit covers RINVOQ™ (upadacitinib) alone or for RINVOQ plus one of the following medications: methotrexate, leflunomide (Arava®), or hydroxychloroquine (Plaquenil®). Eligibility: Available to patients with commercial prescription insurance coverage for RINVOQ who meet eligibility criteria. Co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patient will no longer be able to use the RINVOQ Complete Savings Card and patient must call RINVOQ Complete at 1.800.2RINVOQ to stop participation. Patients residing in or receiving treatment in certain states may not be eligible. Patients may not seek reimbursement for value received from the RINVOQ Complete program from any third-party payers. Offer subject to change or discontinuance without notice. Restrictions, including monthly maximums, may apply. This is not health insurance.
Arava and Plaquenil are registered trademarks of their respective owners.

‡Program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patient will no longer be eligible to participate in program. Available to patients between the ages of 18-63 with commercial prescription insurance coverage who meet eligibility criteria. Eligibility: Patients must be diagnosed with moderate to severe rheumatoid arthritis, have a valid prescription for RINVOQ™ and participate in a commercial insurance plan that has denied or not yet made a formulary decision for RINVOQ. Once the patient’s insurance plan has made a formulary decision and established a process for reviewing coverage requests for RINVOQ, continued eligibility for the program requires the submission of a Prior Authorization prior to the next scheduled dose and appeal of the coverage denial within 180 days. Program provides RINVOQ at no charge to patients for up to 2 years or until they receive insurance coverage approval, whichever occurs earlier. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage.

Complete app

RINVOQ COMPLETE APP

Track treatment

The Complete App helps patients start and stay on track with their prescribed treatment:

  • For eligible patients, provide access to savings resources
  • Fit RINVOQ into their personal routines along with customized reminders
  • Log symptoms
  • Identify and track progress towards personal goals

Coming soon, RINVOQ patients will be able to use the RINVOQ Complete App.

Get it on Google Play
Download on the App Store
Computer monitor, keyboard and mouse

COMPLETEPRO.COM

Streamline the Rx process

CompletePro.com enables seamless enrollment into RINVOQ Complete, and helps streamline the prescription process for your patients.

 

With CompletePro.com, you can:

  • Request benefits verifications
  • Complete and submit prior authorizations
  • Send prescriptions to the patient’s specialty pharmacy of choice, with the option to include a savings card
  • Track and monitor where patients are in the prescription process
brushstroke
brushstroke
Downloadable resources Downloadable resources Downloadable resources

Download forms to help patients get the support they need
to start and stay on track with RINVOQ

PRACTICE FORMS AND RESOURCES

To enroll a patient in RINVOQ Complete:

1

Fill out the form with your patient
This form enrolls your patient and can be used to initiate a prescription with your patient’s preferred speciality pharmacy.

2

Fill out the patient support prescription in Section 6
This may help your commercially insured patients get access to RINVOQ if they experience a delay or denial in their insurance coverage.*

3

Fax the form to 1-678-727-0690
You will receive a call from an Access Specialist to discuss next steps. In addition, fax the form to your patient’s specialty pharmacy if using the Pharmacy Prescription in Section 9.

4

Inform your patient that they have been enrolled
Let your patient know that they will be receiving a call from their Nurse Ambassador.

Get started with
the enrollment &
prescription form

*Program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patient will no longer be eligible to participate in program. Available to patients between the ages of 18-63 with commercial prescription insurance coverage who meet eligibility criteria. Eligibility: Patients must be diagnosed with moderate to severe rheumatoid arthritis, have a valid prescription for RINVOQ™ and participate in a commercial insurance plan that has denied or not yet made a formulary decision for RINVOQ. Once the patient’s insurance plan has made a formulary decision and established a process for reviewing coverage requests for RINVOQ, continued eligibility for the program requires the submission of a Prior Authorization prior to the next scheduled dose and appeal of the coverage denial within 180 days. Program provides RINVOQ at no charge to patients for up to 2 years or until they receive insurance coverage approval, whichever occurs earlier. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage.

ACCESS AND REIMBURSEMENT FORMS

RINVOQ Complete is here to help your patients get timely access to RINVOQ. Along with requesting information from a RINVOQ Complete Access Specialist, you can download the forms you need to get started.

Templates

This information is for informational purposes only and is not intended to provide reimbursement or legal advice. The information presented here does not guarantee payment or coverage.

Instructions

Here you can download helpful guidelines and tips for completing these templates.

This information is for informational purposes only and is not intended to provide reimbursement or legal advice. The information presented here does not guarantee payment or coverage.

Billing and Coding

Specialty Pharmacy

Too many forms?

Offer enrollment to patients and submit forms electronically with

PATIENT FORMS AND RESOURCES

RINVOQ COMPLETE ENROLLMENT

Once you and your patient complete the RINVOQ Complete Enrollment and Prescription Form, simply fax it to RINVOQ Complete and inform your patient that they will be receiving a call from their Nurse Ambassador. If you complete the Pharmacy Prescription, also fax it to your patient’s chosen specialty pharmacy.

Download Enrollment
& Prescription Form:

ADDITIONAL RESOURCES

 

See how COMPLETE PRO can help streamline your prescription process

Seamlessly enroll patients into RINVOQ Complete, request benefit verifications, send prior authorizations, and more.

See RINVOQ dosing information

View dosing recommendations for RINVOQ, the first once-daily JAK1-selective inhibitor in RA.

INDICATION1

RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine, is not recommended.

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking

INDICATION1

RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine, is not recommended.

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking